Characterizing Sensitivity to Vincristine, Irinotecan, and Telomerase-targeted Therapy in Diffuse Anaplastic Wilms Tumor Patient-derived Xenografts☆
Author / Expert
Daniel B. Gehle, Carolyn M. Jablonowski, Prahalathan Pichavaram, Shivendra Singh, Mary A. Woolard, Christopher L. Morton, Catherine A. Billups, Andrew M. Davidoff, Jun Yang, Andrew J. Murphy
Topic overview
Patients with diffuse anaplastic Wilms tumor (DAWT) experience relatively poor oncologic outcomes. Previous work has described mechanisms of telomerase upregulation in DAWT, posing a potential therapeutic target.
Comments